India Markets closed
  • BSE SENSEX

    48,564.27
    -470.40 (-0.96%)
     
  • Nifty 50

    14,281.30
    -152.40 (-1.06%)
     
  • Dow

    30,814.26
    -177.24 (-0.57%)
     
  • Nasdaq

    12,998.50
    -114.10 (-0.87%)
     
  • BTC-INR

    2,663,899.75
    +26,329.50 (+1.00%)
     
  • CMC Crypto 200

    706.12
    -29.02 (-3.95%)
     
  • Hang Seng

    28,862.77
    +288.91 (+1.01%)
     
  • Nikkei

    28,242.21
    -276.97 (-0.97%)
     
  • EUR/INR

    88.4076
    +0.0310 (+0.04%)
     
  • GBP/INR

    99.1975
    -0.1999 (-0.20%)
     
  • AED/INR

    19.8870
    +0.0130 (+0.07%)
     
  • INR/JPY

    1.4130
    -0.0031 (-0.22%)
     
  • SGD/INR

    55.0000
    -0.0230 (-0.04%)
     

Inovio to begin mid-to-late stage study of COVID-19 vaccine candidate in September

News18
·1-min read

Inovio Pharmaceuticals Inc expects its experimental COVID-19 vaccine to enter mid-to-late stage study in September and secure U.S. emergency use authorization sometime in 2021, the U.S. vaccine developer said on Monday.

The Plymouth Meeting, Pennsylvania-based company had previously said it would begin mid-stage human studies for the vaccine candidate, INO-4800, this summer.

Shares of the company were down 6% in trading after the bell.

Inovio is in active talks with the U.S. Food and Drug Administration and awaits the agency’s approval to begin Phase 2/3 study in September, a company executive said during a post-earnings conference call.

The company in June reported encouraging results from an early stage human trial and received $71 million from the U.S. Department of Defense to scale up production of devices used to administer INO-4800.

Effective vaccines are seen as essential to controlling the pandemic that has claimed more than 731,700 lives worldwide, according to a Reuters tally.

Many drugmakers, including Moderna Inc, Pfizer Inc, Johnson & Johnson, Sanofi and AstraZeneca Plc, are also in various stages of developing a vaccine for COVID-19.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor